secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001297184-24-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q2 revenue $182.4M, adjusted EPS $0.94; both up ~25-45% YoY
---------------------------------------------------------------------

- Net revenues $182.4M (Q2) vs $145.7M YoY; six-month $354.2M vs $285.7M.
- GAAP net income $37.9M ($0.73 diluted EPS) vs $26.1M ($0.49) YoY.
- Adjusted non-GAAP net income $48.7M ($0.94 diluted EPS) vs $34.8M ($0.65) YoY.
- CEO highlighted BAQSIMI as a leading portfolio driver amid transition to branded/biosimilar products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718424000045/0001297184-24-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718424000045/amph-20240807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-24-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer